Dr. Aaron Meyer's research focuses on pairing experiments with data-driven modeling to learn about cancer biology and innate immune signaling. His projects include:
- activation models of innate immune receptors (TAM RTKs, FcgRs, interferons, class I cytokine receptors) to understand their regulation across cell populations and the influence of cell-cell heterogeneity
- studying sets of targeted therapy resistance mechanisms to identify molecular commonalities and markers of response to combination therapy.
Manole S, Richards EJ, Meyer AS. JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies. Cancer Res. 2016 Sep 15;76(18):5219-28. doi: 10.1158/0008-5472.CAN-16-0123. Epub 2016 Jul 22.
Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov. 2016 Apr;6(4):382-99. doi: 10.1158/2159-8290.CD-15-0933. Epub 2016 Mar 16.
Meyer AS, Zweemer AJ, Lauffenburger DA. The AXL Receptor is a Sensor of Ligand Spatial Heterogeneity. Cell Syst. 2015 Jul 29;1(1):25-36.
Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal. 2013 Aug 6;6(287):ra66. doi: 10.1126/scisignal.2004155.
Meyer AS, Hughes-Alford SK, Kay JE, Castillo A, Wells A, Gertler FB, Lauffenburger DA. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J Cell Biol. 2012 Jun 11;197(6):721-9. doi: 10.1083/jcb.201201003. Epub 2012 Jun 4.